New York — A Wall Street research firm is warning that the rising popularity of GLP-1 weight-loss medications such as Ozempic could fundamentally alter the economics of the fast-food industry, with McDonald's potentially facing a $482 million annual revenue hit.
Redburn Atlantic, a financial services firm, has placed McDonald's stock in its "bear" category after a week in which the company's shares lost roughly 3 percent of their value. The move reflects analysts' growing conviction that drugs designed to treat diabetes and obesity are reshaping how consumers approach eating out.
In a research note reported by CBS News, the analysts argue that lower-income individuals who begin taking these medications are likely to reduce spending on food prepared outside the home. Higher-income users, they note, may initially cut back but tend to revert to previous spending patterns within about a year.
"Behaviour changes extend beyond the individual user — reshaping group dining, influencing household routines and softening habitual demand," the analysts wrote. "A 1 percent drag today could easily build to 10 percent or more over time, particularly for brands skewed toward lower income consumers or group occasions."
The potential financial impact is significant for McDonald's, which could see 28 million fewer customer visits annually if the trend materializes. That translates to an estimated $482 million in lost sales each year, according to the analysts' calculations.
However, the scenario remains speculative. Only about 6 percent of American adults currently use these medications, and their high cost — starting at roughly $900 per month — puts them out of reach for many lower-income households, the very demographic that fast-food chains rely on most heavily.
Policy Shifts Could Accelerate Adoption
Some policymakers are exploring ways to reduce the price of GLP-1 drugs, which have been shown to aid weight loss and offer additional health benefits, including potential cancer prevention and addiction treatment. If legislative efforts succeed in making these medications more affordable, the analysts suggest that fast-food chains could face a more rapid erosion of demand.
The implications extend beyond McDonald's, as other quick-service restaurants that cater to budget-conscious diners and group occasions may be similarly vulnerable. The analysts' report highlights how a single medical innovation can ripple through unrelated industries, forcing companies to adapt to shifting consumer behavior.
For now, McDonald's and its peers continue to operate in an environment where the drugs' impact is more theoretical than real. But the Redburn Atlantic note serves as a reminder that long-term planning in the food service sector must account for demographic and health trends that could alter eating habits in ways that are difficult to reverse.





